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BACKGROUND AND PURPOSE
C-type natriuretic peptide (CNP) is an endothelium-derived vasorelaxant, exerting anti-atherogenic actions in the vasculature
and salvaging the myocardium from ischaemic injury. The cytoprotective effects of CNP are mediated in part via the
Gi-coupled natriuretic peptide receptor (NPR)3. As GPCRs are well-known to control cell proliferation, we investigated if NPR3
activation underlies effects of CNP on endothelial and vascular smooth muscle cell mitogenesis.
EXPERIMENTAL APPROACH
Proliferation of human umbilical vein endothelial cells (HUVEC), rat aortic smooth muscle cells (RAoSMC) and endothelial and
vascular smooth muscle cells from NPR3 knockout (KO) mice was investigated in vitro.
KEY RESULTS
CNP (1 pM–1 mM) facilitated HUVEC proliferation and inhibited RAoSMC growth concentration-dependently. The pro- and
anti-mitogenic effects of CNP were blocked by the NPR3 antagonist M372049 (10 mM) and the extracellular signal-regulated
kinase (ERK) 1/2 inhibitor PD98059 (30 mM) and were absent in cells from NPR3 KO mice. Activation of ERK 1/2 by CNP was
inhibited by Pertussis toxin (100 ng·mL-1) and M372049 (10 mM). In HUVEC, ERK 1/2 activation enhanced expression of the
cell cycle promoter, cyclin D1, whereas in RAoSMC, ERK 1/2 activation increased expression of the cell cycle inhibitors
p21waf1/cip1 and p27kip1.
CONCLUSIONS AND IMPLICATIONS
A facet of the vasoprotective profile of CNP is mediated via NPR3-dependent ERK 1/2 phosphorylation, resulting in
augmented endothelial cell proliferation and inhibition of vascular smooth muscle growth. This pathway may offer an
innovative approach to reversing the endothelial damage and vascular smooth muscle hyperplasia that characterize many
vascular disorders.
Abbreviations
ANP, atrial natriuretic peptide; CNP, C-type natriuretic peptide; ERK 1/2, extracellular signal-regulated kinase 1/2;
HUVEC, human umbilical vein endothelial cell; I/R, ischaemia reperfusion; ICAM-2, intercellular adhesion molecule-2;
KO, knockout; NPR3, natriuretic peptide receptor-3; PCI, percutaneous coronary intervention; PMEC, pulmonary
microvascular endothelial cells; RAoSMC, rat aortic smooth muscle cells; WT, wild type
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Introduction
A key role for C-type natriuretic peptide (CNP) in regulating
cardiac and vascular function has recently emerged (Ahluwa-
lia and Hobbs, 2005; Potter et al. 2009). This cardiovascular
homeostatic role is perhaps best exemplified by its ability to
control blood flow in the resistance vasculature (Chauhan
et al., 2003), to reduce the reactivity of leukocytes and plate-
lets (Scotland et al., 2005), to govern the pacemaker current
in the heart (Rose et al., 2004) and to protect against myo-
cardial ischaemia/reperfusion (I/R) injury (Hobbs et al., 2004;
Wang et al. 2007) and cardiac hypertrophy (Tokudome et al.,
2004; Soeki et al. 2005; Wang et al., 2007). In contrast to the
endocrine actions of atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP), the vascular actions of CNP
are autocrine or paracrine in nature, as this peptide is stored
and released by vascular endothelial cells (Suga et al., 1992;
Chen and Burnett, Jr, 1998). This local endothelial produc-
tion, coupled to the vasodilator, anti-platelet and anti-
leukocyte effects of CNP, imply it has the potential to exert a
multi-pronged anti-atherosclerotic influence on the blood
vessel wall. This concept is supported by several previous
reports. For example, adenoviral delivery of CNP slows
neointimal hyperplasia and promotes re-endothelialization
in vein grafts (Ohno et al., 2002) and following balloon
angioplasty (Ueno et al., 1997; Morishige et al. 2000; Doi
et al., 2001; Kuhnl et al., 2005; Pelisek et al. 2006), and main-
tains blood flow and capillary density after hind-limb
ischaemia (Yamahara et al., 2003). Furthermore, systemic
infusion of CNP prevents development of intimal thickening
in damaged carotid arteries (Furuya et al., 1993) and increases
the number of proliferating endothelial cells in pulmonary
hypertension (Itoh et al., 2004). CNP expression is also
highly up-regulated in human coronary atherosclerotic
lesions (Naruko et al., 1996) and in the neointima following
percutaneous coronary intervention (PCI) (Naruko et al.,
2005). CNP’s sibling, ANP, has been shown to act in an
endocrine manner to facilitate re-vascularization after I/R
injury (Kuhn et al., 2009).
Activation of the guanylate cyclase-linked natriuretic
peptide receptor NPR2 (receptor nomenclature follows Alex-
ander et al., 2009) underlies many of the biological actions of
CNP (Ahluwalia et al., 2004), but recent evidence suggests
that several cardioprotective effects (vasodilatation of the
resistance vasculature, anti-platelet and anti-leukocyte
effects) of the peptide are dependent on a different receptor,
NPR3 (Hobbs et al., 2004; Rose et al. 2004; Ahluwalia and
Hobbs, 2005). Unlike other NPR subtypes, NPR3 does not
possess a guanylate cyclase functionality but rather possesses
a short 37amino acid intracellular tail that contains a Gi/o-
binding domain (Anand-Srivastava et al., 1996; Murthy and
Makhlouf, 1999). As a consequence, G-protein coupling
confers a positive signalling role to NPR3 in certain tissues,
including inhibition of adenylate cyclase activity (Pagano
and Anand-Srivastava, 2001) and activation of phospholipase
C-b3 (Murthy et al., 2000). NPR3 is a homodimer with each
subunit possessing a single transmembrane domain (He et al.,
2001). This structure is quite distinct from the archetypal
heptahelical GPCR family (Gudermann et al. 1995; Nurnberg
et al., 1995; Gether, 2000) and more like the Gi/o-coupled
growth factor receptors, such as those triggered by
sphingosine-1-phosphate and insulin-like growth factor-1
(Zondag et al., 1998; Hallak et al. 2000). This raises the possi-
bility that NPR3/Gi/o signalling may play a key role in gov-
erning cell proliferation.
Indeed, an important facet of CNP bioactivity that con-
tributes to its cardioprotective function is an ability to
promote re-endothelialization (Furuya et al. 1993; Ueno et al.,
1997; Morishige et al., 2000; Doi et al. 2001; Ohno et al.,
2002; Yamahara et al., 2003; Kuhnl et al. 2005; Pelisek
et al., 2006) while concomitantly inhibiting vascular smooth
muscle cell growth (Furuya et al., 1993; Cahill and Hassid,
1994; Hutchinson et al., 1997). This dichotomous activity
may prove important not only in understanding the mecha-
nisms underpinning vascular homeostasis but may also offer
a pharmacological means to differentially regulate endothe-
lial and vascular smooth muscle cell proliferation to slow
pathogenesis and facilitate tissue repair in diseased blood
vessels. If this therapeutic potential of CNP is to be harnessed,
it is imperative that mechanisms underlying this unique
pharmacodynamic profile are delineated.
Although the guanylate cyclase-linked NPR2 has been
documented to reduce vascular smooth muscle cell growth
in a cGMP-dependent manner, the potential for the Gi/o-
coupled NPR3 to act as a regulator of cell growth in the
vasculature has not been elucidated. Here, we have sought
to characterize the role of CNP/NPR3 signalling in endothe-
lial and vascular smooth muscle cell proliferation and define
the subcellular signalling cascades that underlie these novel
actions.
Methods
Animals
All animal care and experimental procedures complied with
the UK Animals (Scientific Procedures) Act 1986 and the
Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication no.
85–23, revised 1996) and were approved by the University
College London Ethics Committee.
Aortic smooth muscle cell (AoSMC) isolation
and characterization
AoSMC were isolated from adult Sprague–Dawley rats (male;
200–250 g) or wild-type (WT) and NPR3 knockout (KO) mice
(male; 25–30 g) by enzymatic digestion, as described previ-
ously (Chamley-Campbell et al., 1979). Cells were used
between passages 4 and 10.
Biomagnetic purification of mouse pulmonary
microvascular endothelial cells (PMEC)
PMEC were isolated from WT and NPR3 KO mice by a com-
bination of methods previously described (Hartwell et al.,
1998; Kuhlencordt et al. 2004). Animals were killed by cervical
dislocation, and the lungs were removed and placed in Dul-
becco’s modified Eagle’s medium (DMEM)/Nutrient Mixture
F12 (DMEM/F12; Invitrogen, Paisley, UK) on ice. The lung
tissue was then washed three times in DMEM/F12, and the
central cartilaginous portion was removed. The remaining
tissue was dissected and incubated with 0.1% collagenase, in
BJPNPR3 modulates vascular cell proliferation
British Journal of Pharmacology (2011) 164 584–597 585
DMEM/F12, for 1 h at 37°C. The tissue was then passed
through a 19-gauge needle to disperse cells and subsequently,
through a 70 mm filter, to remove debris. The cells were cen-
trifuged (200¥ g, 5 min, 21°C) and then re-suspended in
DMEM/F12 containing 20% heat-inactivated foetal calf serum
(HI FCS), penicillin (100 U·mL-1), streptomycin (100 mg·mL-1),
endothelial cell growth supplement/heparin (1 mL·mL-1; Pro-
mocell, Heidelberg, Germany) and endothelial cell growth
supplement (50 mg·mL-1). Cells were grown in a 0.1% gelatine-
coated flask in a humidified incubator with 5% CO2 in air at
37°C. The media were changed after 24 h and changed every
2/3 days until cells were 80–90% confluent; Dynabeads (4 ¥
106) coated in sheep anti-rat IgG (Invitrogen) were washed
three times in PBS and then incubated overnight with 5 mg
anti-intercellular adhesion molecule (ICAM)-2 (CD102,
endothelial specific marker; BD Biosciences, Oxford, UK) on a
rotator. The Dynabeads were then washed three times in PBS,
media were aspirated and the Dynabeads were added to the
isolated pulmonary vascular cells for 1 h in a humidified
incubator at 37°C. Cells were then trypsinized and magneti-
cally separated. Cells were washed andmagnetically separated
a second time and then plated on a 0.1% gelatin-coated flask.
Cells displayed a typical cobblestone appearance (data not
shown) and were used up to passage 4.
Due to the severely reduced fecundity and viability of
NPR3 KO animals, the availability of PMEC from these mice
was significantly restricted and prevented more extensive
studies employing NPR3-deficient cells.
Assessment of cell proliferation by
5-bromo-2-deoxyuridine (BrdU) incorporation
AoSMC were seeded into 96-well plates at a density of 25 x
103 cells·per well (rat) or 10 x 103 cells·per well (mouse) in
triplicate, in DMEM containing penicillin (100 U·mL-1),
streptomycin (100 mg·mL-1), L-glutamine (2 mM) and 10%
FCS for 24 h in a humidified incubator with 5% CO2 in air.
HUVEC (Promocell; Heidelberg, Germany) were plated into
96-well plates at a density of 1000 cells·per well in triplicate,
in EGMTM-2 medium supplemented with a Bullet kit for 24 h
in a humidified incubator with 5% CO2 in air. PMEC were
seeded at 500 cells·per well (96-well plate) for 24 h in growth
medium (as above).
Cell proliferation was assessed by determining BrdU
incorporation using a commercially available assay (Roche
Diagnostics, East Sussex, UK). Proliferation was determined in
an essentially identical manner for each cell type. Cells were
exposed to media (DMEM for AoSMC and PMEC; EGMTM-2
for HUVEC) containing 0.1% HI FCS (without supplementa-
tion for endothelial cells) for 24 h to stop growth. Cells were
then returned to corresponding media containing 10% HI
FCS (including supplements for endothelial cells) and treated
with CNP (ranging from 1 pM–1 mM depending on the cell
type) in the absence and presence of inhibitors or vehicle
(where appropriate) for 24 h. BrdU was added during the S
phase (20 h post treatment), and incorporation was measured
at 24 h.
Parallel experiments were also conducted to confirm that
BrdU incorporation matched cell number under representa-
tive conditions. Here, cells were counted using a haemocy-
tometer following Trypan blue staining at 24 h.
Immunoblotting
RAoSMC and HUVEC were seeded in 10 cm culture dishes
and incubated at 37°C in a humidified incubator containing
5% CO2 in air until confluent. AoSMC were treated with CNP
(1 mM) for 0, 5, 10, 15, 30, 60, 90 or 120 min, and HUVEC
were treated with CNP (100 pM) for 0, 0.5, 1, 3, 6 or 24 h. In
certain experiments, cells were pre-incubated with the Gi/o
G-protein inhibitor Pertussis toxin (100 ng·mL-1; 16 h) or the
selective NPR3 antagonist M372049 (Veale et al., 2000; Villar
et al., 2007; 10 mM; 30 min). The medium was then removed,
and cells were washed with PBS. Phospho-homogenization
buffer [Tris (10 mM), pH 7.4, NaCl (50 mM), NaPPi (30 mM),
EDTA (2 mM), NaF (50 mM), 1% Triton X-100, phenylmeth-
ylsulfonyl fluoride (1 mM), Na3VO4 (1 mM) and benzami-
dine, leupeptin, antipain and aprotinin; all (1 mg·mL-1)] was
added. Cells were scraped, transferred to 1.5 mL tubes and
centrifuged (13 793¥ g, 5 min, 4°C). Supernatants were
retained and analysed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (as described previously;
Connelly et al., 2003) using the following primary antibodies:
anti-p44/p42 and anti-phospho-p44/p42 [Thr202/Tyr204] (both
1:500; New England Biolabs, Hertfordshire, UK), anti-cyclin
D1 (1:1000), anti-p27kip1 (1:1000; both New England Biolabs)
and anti-p21waf1/cip1 (1:500; BD Pharmingen, Oxford, UK).
RNA isolation and RT-PCR
Total RNA was extracted from RAoSMC and HUVEC (~5 ¥ 106
cells) using the RNeasy mini kit (Qiagen, West Sussex, UK),
and RT-PCR was carried out using a One-Step RT-PCR kit
(Qiagen), as we have described previously (Connelly et al.,
2003). Reverse transcription was carried out at 50°C for
30 min followed by thermal cycling conditions as follows:
95°C for 15 min, 35 cycles of denaturation at 94°C for 1 min,
annealing at 55°C for 1 min and extension at 72°C for 1 min,
followed by a final extension at 72°C for 10 min. PCR prod-
ucts were resolved on a 1% agarose gel.
The primer sequences (Sigma Genosys, Cambridgeshire,
UK) used for RAoSMC and HUVEC are shown in Tables 1 and
2 respectively.
Measurement of cGMP
Cellular cGMP concentrations were measured using a com-
mercially available assay (R&D Systems, Oxford, UK), as
described previously (Baliga et al., 2008).
Data analysis
All statistical analyses were performed using GraphPad Prism
(GraphPad Software, San Diego, CA). Densitometric analyses
were performed using AlphaEaseFC (AlphaInnotech,
Cannock, UK). All data are plotted graphically as mean
values, with vertical bars representing standard error of the
mean (SEM). One-way ANOVA followed by Bonferroni’s mul-
tiple comparison test was used to assess differences between
individual experimental conditions.
Materials
All reagents were purchased from Sigma-Aldrich (Poole, UK),
except for SB203580 and SP600125, which were obtained
from Axxora, Nottingham, UK.
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Results
NPR-C underpins the pro- and
anti-proliferative effects of CNP
CNP (1 nM–1 mM) caused a concentration-dependent inhibi-
tion of cell proliferation in RAoSMC, whereas in HUVEC,
CNP (1 pM–1 nM) caused a concentration-dependent aug-
mentation of cell growth (of equal magnitude to vascular
endothelial growth factor (VEGF) 10 ng·mL-1; data not
shown; Figure 1). Representative studies also confirmed that
BrdU incorporation was representative of cell number (data
not shown). From these data, concentrations of CNP that
elicited maximal effects in vascular smooth muscle and
endothelial cells (1 mM and 100 pM, respectively) were
chosen for further experimentation.
In RAoSMC, CNP (1 mM) significantly inhibited cell pro-
liferation, an effect that was attenuated in the presence of the
selective NPR3 antagonist M372049 (Veale et al., 2000; Villar
et al., 2007) (10 mM; Figure 1). In WT mouse AoSMC, CNP
(1 mM) produced a marked inhibition of growth; however, in
AoSMC from NPR3 KO mice, the inhibitory effect of CNP was
absent (Figure 2). The basal growth of AoSMC from NPR3 KO
mice was significantly increased in comparison to WT mouse
AoSMC (Figure 2).
In HUVEC, CNP (100 pM; Figure 1) and the selective
NPR3 agonist cANF4–23 (100 pM; data not shown) stimulated
cell growth; the proliferative effect of both peptides was
blocked by M372049 (10 mM). CNP (100 pM) increased pro-
liferation in WT PMEC, whereas in PMEC from NPR3 KO
mice, CNP (100 pM) had very little effect (Figure 2). More-
over, the basal growth of PMEC from NPR3 KO mice was
lower in comparison with that of WT PMEC (Figure 2).
Identification of NPRs in AoSMC
and HUVEC
To confirm the expression of NPR3, and other NPR subtypes,
in vascular smooth muscle and endothelial cells, RT-PCR was
carried out on total RNA isolated from RAoSMC and HUVEC.
mRNA for all three natriuretic peptide receptors (NPR1, NPR2
and NPR3) was detected in both cell types (Figure 3).
Determination of cellular cGMP levels in
response to CNP
In order to provide further evidence that activation of NPR2,
and consequent increases in cellular cGMP concentrations do
not underpin the effects of CNP on RAoSMC and HUVEC,
cGMP levels were measured in both cell types.
Basal cGMP concentrations were 10-fold higher in
RAoSMC compared with HUVEC (Figure 3). CNP (1 mM
RAoSMC; 100 pM HUVEC) increased cGMP concentrations
in RAoSMC and HUVEC approximately sevenfold and
twofold respectively. In both cells types, the increase in cGMP
produced by CNP was identical in the presence of M372049
(10 mM; Figure 3), a concentration of the NPR3 antagonist
that significantly reversed the effects of CNP on cell growth
(Figure 1).
Table 1
Primer sequences and product sizes used for NPR mRNA determination in RAoSMC
Receptor Primer sequence Product size
NPR1 Sense 5′-CATCCTGGACAACCTGC-3′ 714
Antisense 5′-TAGGTCCGAACCTTGCC-3′
NPR2 Sense 5′-CATGGCAGGACAATCGAACC-3′ 720
Antisense 5′-TGCCTGCACCTTTGTGATATCG-3′
NPR3 Sense 5′-GGCTCAATGAGGAGGATTACGTG-3′ 558
Antisense 5′-AATCTTCCCGCAGCTCTCGATG-3′
Table 2
Primer sequences and product sizes for NPR mRNA determination in HUVEC
Receptor Primer sequence Product size
NPR1 Sense 5′-CATCCTGGACAACCTGC-3′ 714
Antisense 5′-TAGGTCCGAACCTTGCC-3′
NPR2 Sense 5′-GGCAGGACAATCGCACCC-3′ 717
Antisense 5′-TGCCTGCACCTTTGTGATAACG-3′
NPR3 Sense 5′-GGCTCAATATGGAGGATTACGTT-3′ 558
Antisense 5′-AATCTTCCCGTAATTCCCGATG-3′
BJPNPR3 modulates vascular cell proliferation
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Extracellular signal regulated kinase (ERK)
1/2 phosphorylation underlies the effects of
CNP/NPR-C on cell growth
Neither the p38 inhibitor SB203580 (30 mM) nor the c-Jun
N-terminal kinase (JNK) inhibitor SP600125 (3 mM) reversed
the effects of CNP on RAoSMC or HUVEC proliferation (data
not shown). However, the ERK 1/2 inhibitor PD98059
(30 mM) attenuated the ability of CNP to both increase
HUVEC growth and reduce RAoSMC proliferation (Figure 4).
In RAoSMC, ERK 1/2 phosphorylation was transiently
and significantly increased in the presence of CNP (1 mM),
with a peak effect observed at 10 min after treatment
(Figure 4); this effect was blocked in the presence of M372049
(10 mM; Figure 5). In HUVEC, CNP (100 pM) elicited a time-
dependent increase in ERK 1/2 phosphorylation (comparable
to that produced by VEGF, 10 ng·mL-1; data not shown),
which reached a maximum at 30 min (Figure 4); again, this
effect was blocked in the presence of M372049 (10 mM;
Figure 5).
In addition, in both cell types, treatment with the Gi/o
inhibitor Pertussis toxin (100 ng·mL-1), at a concentration
that blocks the vasorelaxant effects of CNP in isolated resis-
tance arteries (Chauhan et al., 2003), abolished CNP-induced
ERK 1/2 phosphorylation (Figure 5).
CNP/NPR-C signalling selectively alters the
expression of cell cycle proteins in RAoSMC
and HUVEC
RAoSMC treated with CNP (1 mM) exhibited a time-
dependent increase in the cell cycle inhibitors p21waf1/cip1 and
p27kip1 (Figure 6), but not the cell cycle promoter cyclin D1
(data not shown). In comparison, HUVEC treated with CNP
Figure 1
The mitogenic effects of CNP are mediated via NPR3. BrdU incorporation in (A) RAoSMC and (B) HUVEC treated with increasing concentrations
of CNP (1 pM–1 mM; 24 h), (C) RAoSMC treated with CNP (1 mM; 24 h) in the absence or presence of M372049 (10 mM) and (D) HUVEC treated
with CNP (100 pM; 24 h) in the absence or presence of M372049 (10 mM). Data shown are means  SEM expressed as a percentage of basal
growth. *P < 0.05 versus basal, #P < 0.05 versus CNP alone. n  12 from 4 separate experiments.
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(100 pM) exhibited a time-dependent increase in cyclin D1
(Figure 6), without a concomitant increase in either p21waf1/cip1
(data not shown) or p27kip1 (data not shown). Pretreatment
with PD98059 (30 mM) reduced the expression of p21waf1/cip1
and p27kip1 in RAoSMC at 24 h and cyclin D1 in HUVEC at
6 h (Figure 7).
Discussion
Endothelium-derived CNP is thought to play a pivotal role in
maintaining the patency and integrity of the blood vessel
wall and opposing pro-atherogenic stimuli (Ahluwalia and
Hobbs, 2005; Potter et al., 2009). A fundamental component
of this function may be a differential effect on endothelial
and vascular smooth muscle growth and such a dichotomous
activity might be exploited pharmacologically to treat several
cardiovascular disorders. For example, in patients undergoing
balloon-angioplasty/percutaneous coronary intervention
(PCI), re-occlusion of the artery often occurs within 6 months
(Fischman et al., 1994; Savage et al., 1998). Such patients are
fitted with a bare metal or drug-eluting stent, which acts as a
platform for new tissue growth. Current drug-eluting stents
release anti-proliferative agents (e.g. sirolimus) that inhibit
vascular smooth muscle proliferation, the predominant cause
of restenosis. However, these drugs also inhibit endothelial
cell proliferation (Matter et al., 2006), which exacerbates the
thrombogenicity of the stent surface. The mitogenic effects of
endothelium-derived CNP on vascular cells along with its
anti-platelet activity (Scotland et al., 2005) therefore provide
a promising target for the treatment of restenosis. The ben-
eficial effects of CNP signalling could be equally applied to
coronary artery bypass graft (CABG) surgery. In this setting,
13% of saphenous vein grafts occlude within the first month
Figure 2
The mitogenic effects of CNP are absent in NPR3 KO cells. BrdU incorporation in WT and NPR3 KO mouse AoSMC and PMEC under basal
conditions (A and B) or treated with CNP (1 mM AoSMC; 100 pM PMEC; 24 h; C and D). Data shown are means SEM expressed as a percentage
of basal growth. *P < 0.05 versus basal or WT. n  12 from 4 separate experiments.
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following surgery, principally due to thrombosis (Bourassa,
1994; Fitzgibbon et al., 1996), and intimal hyperplasia
severely affects a further 10% of grafts within one year
(Bourassa, 1994; Fitzgibbon et al., 1996). Here too, pharma-
cological manipulation to mimic CNP signalling may be of
therapeutic benefit. Indeed, in vivo studies have shown CNP
to be beneficial following balloon angioplasty and vein graft-
ing (Doi et al., 2001; Ohno et al., 2002; Qian et al., 2002;
Pelisek et al., 2006). Nonetheless, the pathways underpinning
the opposing effects of CNP on endothelial and vascular
smooth muscle cells remain unclear.
Here, we have uncovered a pivotal role for NPR3 in
executing these disparate actions of CNP on proliferation of
the endothelium and vascular smooth muscle. The pro-
mitogenic effect of CNP in HUVEC was blocked by selective
NPR3 antagonism with M372049, inhibition of NPR3-linked
Gi/o protein activity by Pertussis toxin and mimicked by the
selective NPR3 agonist cANF4–23, each confirming that NPR3 is
the primary receptor involved. In contrast, CNP caused a
marked inhibition of RAoSMC growth that was blocked in
the presence of the NPR3 antagonist and Pertussis toxin, again
confirming the reliance on Gi-coupled NPR3 for these (anti-
mitogenic) effects. This reliance on NPR3 was substantiated
by measurement of cGMP formation in RAoSMC and HUVEC
in response to CNP. In both cell types, CNP caused an iden-
tical increase in cGMP concentration in the absence and
presence of M372049. As this NPR3 antagonist reversed the
effects of CNP on cell growth, but did not alter cGMP gen-
eration, the clear deduction is that the underpinning mecha-
nism is cGMP-independent. Finally, and perhaps most
convincingly, the pro- and anti-proliferative effects of CNP
were absent in endothelial cells and vascular smooth muscle
cells isolated from NPR3 KOmice. Indeed, the basal growth in
cells lacking NPR3 reflected loss of CNP-dependent signal-
ling; that is, NPR3 KO vascular smooth muscle cells prolifer-
ated more quickly, whereas NPR3 KO endothelial cells
exhibited a reduced mitogenesis. Therefore, whilst NPR2 and
cyclic GMP-dependent inhibition of vascular smooth muscle
Figure 3
NPR expression and cGMP formation in RAoSMC and HUVEC. RT-PCR analysis of NPR1 (labelled A), NPR2 (B) and NPR3 (C) mRNA expression in
(A) RAoSMC and (B) HUVEC (gels representative of three separate experiments). Formation of cGMP in response to CNP in RAoSMC (1 mM; C)
and HUVEC (100 pM; D) in the absence and presence of M372049 (10 mM). *P < 0.05 versus basal. n = 9 observations from three separate
experiments.
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cell proliferation undoubtedly underlie some of the vasopro-
tective actions of CNP (Furuya et al., 1991; 1993; Hutchinson
et al., 1997), and despite the fact that our data confirm that
HUVEC and RAoSMC express both NPR2 and NPR3 (at least
at the mRNA level), our present study suggests that it is NPR3,
primarily, that underlies the dichotomous activity of CNP on
endothelial and vascular smooth muscle cell mitogenesis.
It is intriguing to note that the disparate effects of CNP on
cell growth occur at distinct concentrations. The ability of
CNP to promote endothelial proliferation is maximal at
<1 nM, whereas the inhibitory action of CNP on vascular
smooth muscle mitogenesis is produced by concentrations of
CNP > 10 nM. This concentration-dependent profile suggests
that, under physiological conditions in which plasma con-
centrations of CNP are ~1 pg·mL-1(~0.5 pM; Potter et al.,
2009), a positive feedback loop facilitating endothelial
renewal may be the predominant mitogenic effect of
(endothelium-derived) CNP, whereas in cardiovascular
disease, in which CNP levels are raised, i.e. in the presence of
atherosclerotic lesions (Naruko et al., 1996), the anti-
mitogenic activity on vascular smooth muscle may become
more overt. Clearly, further study in this regard is warranted.
We have also delineated the intracellular pathways that
mediate the disparate proliferative effects of CNP/NPR-C sig-
nalling on endothelial and vascular smooth muscle cells.
Exposure of vascular smooth muscle cells to CNP causes a
rapid, transient increase in the phosphorylation of ERK 1/2, a
key arm of the mitogen activated protein kinase cascade that
is well established to regulate cell growth (Zondag et al., 1998;
Hallak et al., 2000; Pearson et al., 2001). Moreover, both NPR3
antagonism and Pertussis toxin attenuate CNP-induced
enhancement in ERK 1/2 phosphorylation, suggesting that
Figure 4
ERK 1/2 phosphorylation underlies the effects of CNP on cell growth. BrdU incorporation (A and B) and levels of total and phospho-ERK 1/2 (C
and D) in RAoSMC (A and C) and HUVEC (B and D) treated with CNP (RAoSMC 1 mM; HUVEC 100 pM; 24 h) in the absence and presence of
PD98059 (30 mM). Total ERK 1/2 and phospho-ERK 1/2 were analysed by Western blot, and bands were quantified by densitometry. Data shown
are means  SEM expressed as a percentage of basal growth or ERK 1/2 phosphorylation. *P < 0.05 versus basal, #P < 0.05 versus CNP alone.
n  8 from 6 separate experiments.
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this CNP-triggered activation of the pathway is also NPR3-
dependent. This dovetails well with the thesis that Gi/o-
coupled NPR3 acts in a similar fashion to analogous, single
transmembrane domain, G-protein-linked, growth factor
receptors (Zondag et al., 1998; Hallak et al., 2000).
To gain mechanistic insight into the cell cycle proteins
modified by CNP/NPR3 in RAoSMC and HUVEC to bring
about anti- and pro- proliferative effects, respectively, the
relative activity of cell cycle proteins was evaluated in each
cell. These data revealed that ultimately, ERK 1/2 activation
increases expression of the cell cycle inhibitors p21waf1/cip1 and
p27kip1, as demonstrated by the ability of PD98059 to block
the inhibition of vascular smooth muscle growth and activa-
tion of p21waf1/cip1 and p27kip1.
Classically, phosphorylation and activation of ERK 1/2 is
associated with a positive effect on cellular proliferation, as is
observed in vascular smooth muscle cells in response to
several mitogens including endothelin-1 and angiotensin II
(Watanabe et al., 1996; Yoshizumi et al., 1998). However,
there are well-documented exceptions to this model. For
example, small GTPases, such as ras and raf, regulate ERK 1/2
activity to integrate extracellular signals with cell growth,
such that activation of ERK1/2 can result in both cell cycle
activation and cell cycle arrest (Olson et al., 1998). In accord
with this finding, activation of ERK 1/2 leads to stimulation
of p21waf1/cip1 and cessation of the cell cycle in a number of cell
types, including vascular smooth muscle (Pumiglia and
Decker, 1997; Olson et al., 1998; Ray et al., 1999). This mecha-
nism appears particularly pertinent to the anti-mitogenic
effects of NO (Ishida et al., 1999; Kibbe et al., 2000; Sato et al.,
2000; Bauer et al., 2001), sodium salicylate (Marra et al., 2000)
and relaxin (Mookerjee et al., 2009), all of which elicit ERK
Figure 5
The NPR3 antagonist M372049 and the Gi-protein inhibitor Pertussis toxin attenuate CNP-induced ERK 1/2 phosphorylation. Levels of total ERK
1/2 and phospho-ERK 1/2 in (A and C) RAoSMC and (B and D) HUVEC treated with CNP (RAoSMC 1 mM, 10 min; HUVEC 100 pM, 30 min) in
the absence and presence of M372049 (10 mM) or Pertussis toxin (PTx; 100 ng·mL-1). Total ERK 1/2 and phospho-ERK 1/2 were analysed by
Western blot, and bands were quantified by densitometry. Data shown are means  SEM expressed as a percentage of basal ERK 1/2
phosphorylation. *P < 0.05 versus basal; #P < 0.05 versus CNP alone. n = 3–4.
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1/2 -dependent up-regulation of p21waf1/cip1 and p27kip1 to
inhibit mitogenesis. It is likely that a similar mechanism is
triggered by CNP.
In HUVEC, however, NPR3-dependent ERK 1/2 phospho-
rylation resulted in an increase in the expression of cyclin D1,
a protein which complexes with cyclin dependent kinase 4/6
to promote progression through the G1 phase of the cell cycle
(Serrano et al., 1993). This observation is compatible with
previous studies in endothelial cells, which show that the
archetypal, endothelial pro-mitogenic mediators VEGF, fibro-
blast growth factor-2 and angiopoietin-1 all trigger
up-regulation of cyclin D1 to promote proliferation (Pedram
et al., 1998; Kanda et al. 2005; Fu et al., 2007). Moreover,
VEGF has been shown to increase cyclin D1 expression,
inhibited by PD98059, thereby implicating ERK 1/2 as a regu-
lator of cyclin D1 expression, as we observed here with CNP
(Pedram et al., 1998; Fu et al., 2007). Again, it is clear that ERK
1/2 phosphorylation is acrtical component of the change in
cell cycle proteins brought about by CNP/NPR-C, as such
changes were absent in the presence of the selective ERK 1/2
inhibitor PD98059.
In summary, we have shown that CNP activation of NPR3
enhanced ERK 1/2 phosphorylation and results in endothe-
lial cell proliferation and, conversely, vascular smooth muscle
cell growth inhibition. These data strengthen the evidence
supporting NPR3 signal transduction as a principal mecha-
nism conveying the anti-atherogenic actions of this peptide.
Together with previous work (Ohno et al., 2002; Qian et al.,
2002; Chauhan et al., 2003; Hobbs et al., 2004; Scotland et al.,
2005), it is clear that CNP has an important role to play
maintaining vascular homeostasis at a local level. The NPR3-
dependent pro- and anti-mitogenic properties highlighted in
this study endorse CNP, and more specifically NPR3 agonists,
as a feasible therapeutic option for the treatment of
Figure 6
CNP disparately regulates cell cycle protein expression in RAoSMC and HUVEC. Expression of (A) p21waf1/cip1 and (B) p27kip1 in RAoSMC treated
with CNP (1 mM; 24 h) and (C) cyclin D1 in HUVEC treated with CNP (100 pM; 24 h). p21waf1/cip1, p27kip1 and cyclin D1 were analysed by Western
blot, and bands were quantified by densitometry. Data shown are means  SEM expressed as a percentage of basal cell cycle protein expression.
*P < 0.05 versus basal. n = 3–4.
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atherosclerosis, restenosis and other inflammatory vascular
disorders.
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